Companies
Innovent Biologics
Suzhou-based innovator of domestic PD-1 inhibitors and biosimilars, exporting oncology biologics under accelerated NMPA pathways.
- Country
- China
mAbs
cn
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Upfront payment of US$1.2 billion and US$350 million from collaborations with Takeda and Eli Lilly, respectively | hkexnews.hk |
| Capacity | 140,000 liters total operational capacity | en.innoventbio.com · investor.innoventbio.com · hkexnews.hk · prnewswire.com |
| Certification | EMA Good Manufacturing Practice (GMP) certificate for Suzhou manufacturing site | hkexnews.hk · prnewswire.com |
| Regulatory approval | 18 approved products in China as of April 2026 | hkexnews.hk |
| Production site | Suzhou (antibody and ADC capacity) and Hangzhou (antibody capacity) | investor.innoventbio.com · hkexnews.hk · prnewswire.com |
| Headcount | Approximately 9,000 employees worldwide (as of August 2026) | stockanalysis.com · prnewswire.com |
| Revenue | RMB 8.6 billion total revenue in the first half of 2026 | prnewswire.com |
Independent sources: en.innoventbio.com · hkexnews.hk · investor.innoventbio.com · prnewswire.com · stockanalysis.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biopharmaceuticals & biomedicines | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.